The estimated Net Worth of Neil F. Mc Farlane is at least $2.86 Million dollars as of 15 May 2019. Mr. Farlane owns over 1,968 units of Adamas Pharmaceuticals Inc stock worth over $221,841 and over the last 8 years he sold ADMS stock worth over $552,531. In addition, he makes $2,080,640 as Chief Executive Officer and Director at Adamas Pharmaceuticals Inc.
Neil has made over 4 trades of the Adamas Pharmaceuticals Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 1,968 units of ADMS stock worth $35,916 on 15 May 2019.
The largest trade he's ever made was selling 11,125 units of Adamas Pharmaceuticals Inc stock on 20 December 2018 worth over $248,310. On average, Neil trades about 1,360 units every 35 days since 2016. As of 15 May 2019 he still owns at least 26,988 units of Adamas Pharmaceuticals Inc stock.
You can see the complete history of Mr. Farlane stock trades at the bottom of the page.
Neil McFarlane serves as Chief Executive Officer, Director of the Company. Mr. McFarlane has served as the Chief Operating Officer of Retrophin, Inc., a biopharmaceutical company, from August 2016 until May 2019, in which position he was responsible for global commercial operations, corporate development, patient services, and program and alliance management. Previously, Mr. McFarlane served as the Vice President, Bone business unit for UCB, Inc., a biopharmaceutical company, since 2013, in which role he was responsible for leading the global collaboration with Amgen, and from 2011 to 2013, Mr. McFarlane was the Vice President and General Manager of the US Immunology business unit at UCB, Inc. Prior to his positions at UCB, Mr. McFarlane held positions of increasing responsibility with Genzyme Corporation, a biotechnology company, and Sangstat Medical Corporation prior to its acquisition by Genzyme. Mr. McFarlane served in the United States Army Reserves and received his B.S. and M.S. in Nursing from the University of Florida. Adamas believes Mr. McFarlane’s position as our Chief Executive Officer and his extensive knowledge of the pharmaceutical industry qualifies him to serve on the Board.
As the Chief Executive Officer and Director of Adamas Pharmaceuticals Inc, the total compensation of Neil McFarlane at Adamas Pharmaceuticals Inc is $2,080,640. There are no executives at Adamas Pharmaceuticals Inc getting paid more.
Neil McFarlane is 47, he's been the Chief Executive Officer and Director of Adamas Pharmaceuticals Inc since 2019. There are 9 older and 2 younger executives at Adamas Pharmaceuticals Inc. The oldest executive at Adamas Pharmaceuticals Inc is Ivan Lieberburg, 70, who is the Independent Director.
Neil's mailing address filed with the SEC is C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA, 02072.
Over the last 11 years, insiders at Adamas Pharmaceuticals Inc have traded over $26,222,162 worth of Adamas Pharmaceuticals Inc stock and bought 1,128,061 units worth $17,799,399 . The most active insiders traders include Point Partners Llcjay Jeffr..., David L Mahoney, and William W. Ericson. On average, Adamas Pharmaceuticals Inc executives and independent directors trade stock every 25 days with the average trade being worth of $254,236. The most recent stock trade was executed by Vijay Shreedhar on 21 June 2021, trading 6,200 units of ADMS stock currently worth $31,992.
Adamas Pharmaceuticals Inc. delivers innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. The company is a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases.
Adamas Pharmaceuticals Inc executives and other stock owners filed with the SEC include: